Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease

Di Sabatino, Antonio, Liberato, Lucio, Marchetti, Monia, Biancheri, Paolo and Corazza, Gino R (2011) Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Internal and Emergency Medicine, 6 (Suppl 1). pp. 17-27. ISSN 1828-0447

Full text not available from this repository.


Inflammatory bowel diseases (IBD), namely Crohn's disease and ulcerative colitis, are burdened by high medical costs which are mostly dependent on hospital inpatient treatment. New biologic therapies, which target specific cytokines in the inflammatory cascade leading to the intestinal lesions, including tumor necrosis factor (TNF)-α, have revolutionized the management of IBD by offering a therapeutic chance to patients in whom conventional therapies failed. However, the relatively high costs of biologic drugs, together with their potential toxicity due to infections and malignancies, have led to debate regarding their indiscriminate use in IBD patients. The purpose of this review is to deal with the optimal use and cost-effectiveness of the two main monoclonal anti-TNF-α agents currently used in the management of IBD patients, i.e. the chimeric human/murine antibody infliximab and the fully human antibody adalimumab.

Item Type: Article
Uncontrolled Keywords: economics,cost-benefit analysis,humans,drug therapy,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Depositing User: LivePure Connector
Date Deposited: 07 Aug 2018 16:30
Last Modified: 22 Oct 2022 04:03
URI: https://ueaeprints.uea.ac.uk/id/eprint/67987
DOI: 10.1007/s11739-011-0673-9

Actions (login required)

View Item View Item